Triptolide circumvents drug-resistant effect and enhances 5-fluorouracil antitumor effect on KB cells

Anti-Cancer Drugs

Volumn 21, Issue 5, 2010, Pages 502-513

  Chen, Yuan Wu ^a,e   Lin, Gu Jiun ^b,c   Chuang, Yi Ping ^c   Chia, Wei Tso ^a   Hueng, Dueng Yuan ^e   Lin, Chih Kung ^e   Nieh, Shin ^e   Sytwu, Huey Kang ^a,b,c,d  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b Graduate Institute of Life Science   (Taiwan)

^c Department of Biology and Anatomy ^*  (Taiwan)

^d Department of Medical Research   (Myanmar)

^e TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

5 fluorouracil; Apoptosis; Multi drug resistance; Synergistic effect; Triptolide

Indexed keywords

CASPASE 3; FLUOROURACIL; MULTIDRUG RESISTANCE PROTEIN; PROTEIN MCL 1; TRIPTOLIDE; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CELL STRAIN KB; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; DRUG RESISTANCE; ENZYME ACTIVATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BODY WEIGHT; CASPASE 3; DITERPENES; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EPOXY COMPOUNDS; FLUOROURACIL; HUMANS; KB CELLS; P-GLYCOPROTEIN; PHENANTHRENES; PROTO-ONCOGENE PROTEINS C-BCL-2; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 77951263904     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328337337c     Document Type: Article

References (31)

1. Kupchan SM, Court WA, Dailey RG Jr, Gilmore CJ, Bryan RF. Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J Am Chem Soc 1972; 94:7194-7195.
2. Chang WT, Kang JJ, Lee KY,Wei K, Anderson E, Gotmare S, et al. Triptolide and chemotherapy cooperate in tumor cell apoptosis. A role for the p53 pathway. J Biol Chem 2001; 276:2221-2227.
3. Kiviharju TM, Lecane PS, Sellers RG, Peehl DM. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002; 8:2666-2674.
4. Yang S, Chen J, Guo Z, Xu XM, Wang L, Pei XF, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003; 2:65-72.
5. Phillips PA, Dudeja V, McCarroll JA, Borja-Cacho D, Dawra RK, Grizzle WE, et al. Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res 2007; 67:9407-9416.
6. Chen YW, Lin GJ, Chia WT, Lin CK, Chuang YP, Sytwu HK. Triptolide exerts anti-tumor effect on oral cancer and KB cells in vitro and in vivo. Oral Oncology 2009; 45:562-568.
7. Guo X, Ma N,Wang J, Song J, Bu X, Cheng Y, et al. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer 2008; 8:375.
8. Liu Q, Chen T, Chen H, Zhang M, Li N, Lu Z, et al. Triptolide (PG-490) induces apoptosis of dendritic cells through sequential p38 MAP kinase phosphorylation and caspase 3 activation. Biochem Biophys Res Commun 2004; 319:980-986.
9. Kim YH, Lee SH, Lee JY, Choi SW, Park JW, Kwon TK. Triptolide inhibits murine-inducible nitric oxide synthase expression by down-regulating lipopolysaccharide-induced activity of nuclear factor-kappa B and c-Jun NH2-terminal kinase. Eur J Pharmacol 2004; 494:1-9.
10. Wartenberg M, Ling FC, Schallenberg M, Bäumer AT, Petrat K, Hescheler J, et al. Down-regulation of intrinsic P-glycoprotein expression in multicellular prostate tumor spheroids by reactive oxygen species. J Biol Chem 2001; 276:17420-17428.
11. Bao X, Cui J, Wu Y, Han X, Gao C, Hua Z, et al. The roles of endogenous reactive oxygen species and nitric oxide in triptolide-induced apoptotic cell death in macrophages. J Mol Med 2007; 85:85-98.
12. Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, et al. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686-1697.
13. Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev 2003; 3:330-338.
14. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, KnightW, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10:257-263.
15. Lin JC, Jan JS, Hsu CY,Wong DY. High rate of clinical complete response to weekly outpatient neoadjuvant chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin. Cancer 1999; 85:1430-1438.
16. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16:1318-1324.
17. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10:1245-1251.
18. Clavel M, Vermorken JB, Cognetti F, Cappelaere P, de Mulder PH, Schornagel JH, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5:521-526.
19. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004; 64:4621-4628.
20. Finlay GJ, Baguley BC,Wilson WR. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal Biochem 1984; 139:272-277.
21. Leonessa F, Green D, Licht T,Wright A,Wingate-Legette K, Lippman J, et al. MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer. Br J Cancer 1996; 73:154-161.
22. Deng L, Tatebe S, Lin-Lee YC, Ishikawa T, Kuo MT. MDR and MRP gene families as cellular determinant factors for resistance to clinical anticancer agents. Cancer Treat Res 2002; 112:49-66.
23. O'Connor R. The pharmacology of cancer resistance. Anticancer Res 2007; 27:1267-1272.
24. Feng G, Wang DZ, Chen HQ, Hu J, He J. A new method to induce multi-drug resistance to carboplatin in a mouse model of human tongue squamous cell carcinoma. Int J Oral Maxillofac Surg 2008; 37:1141-1147.
25. Yoshida N, Takagi A, Kitazawa H, Kawakami J, Adachi I. Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus. Toxicol Appl Pharmacol 2005; 209:167-173.
26. Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 2002; 99:1885-1893.
27. Nakagawa Y, Abe S, Kurata M, Hasegawa M, Yamamoto K, Inoue M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol 2006; 81:824-831.
28. Chen YW, Lin GJ, Chia WT Triptolide exerts anti-tumor effect on oral cancer cells in vitro and in vivo. Oral Oncol 2009. In press
29. He MF, Liu L, GeW, Shaw PC, Jiang R,Wu LW, et al. Antiangiogenic activity of Tripterygium wilfordii and its terpenoids. J Ethnopharmacol 2009; 121:61-68.
30. Zhu W, Ou Y, Li Y, Xiao R, Shu M, Zhou Y, et al. A small-molecule triptolide suppresses angiogenesis and invasion of human anaplastic thyroid carcinoma cells via down-regulation of the nuclear factor-kappa B pathway. Mol Pharmacol 2009; 75:812-819.
31. Tang XY, Zhu YQ, Tao WH, Wei B, Lin XL. Synergistic effect of triptolide combined with 5-fluorouracil on colon carcinoma. Postgrad Med J 2007; 83:338-343.